METTL16 Antagonizes MRE11-Mediated DNA End Resection and Confers Synthetic Lethality to PARP Inhibition in Pancreatic Ductal Adenocarcinoma

Scientists reporteed that PDAC with elevated expression of METTL16, one of the ‘writers’ of RNA N6-methyladenosine modification, may benefit from poly-(ADP-ribose)-polymerase inhibitor treatment.